Related Experiment Video
Updated: May 13, 2025
07:06
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
32.7K
Quetiapine and Paediatric Psychiatrica: Evidence or Diffidence?
Ahmed Naguy1, Saxby Pridmore2, Hend Fm Fr Alenezi3
1Naguy, MBBch, MSc, MRCPsych (UK), Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait.
Psychopharmacology Bulletin
|April 14, 2025
Summary
Quetiapine, an atypical antipsychotic, is FDA-approved for childhood-onset schizophrenia and juvenile bipolar disorder. This review examines its clinical uses and supporting evidence in child and adolescent psychiatry.
Area of Science:
- Child and Adolescent Psychiatry
- Pharmacology
- Clinical Therapeutics
Background:
- Quetiapine is an atypical antipsychotic with an established market presence.
- It holds FDA approval for specific pediatric mental health conditions.
Purpose of the Study:
- To review the established clinical indications of quetiapine in child and adolescent psychiatry.
- To examine the existing evidence supporting its therapeutic use in this population.
Main Methods:
- Focused literature review.
- Examination of extant clinical evidence.
Main Results:
- Quetiapine is approved for childhood-onset schizophrenia.
- Quetiapine is approved for juvenile bipolar mood disorder.
- Its pharmacological profile suggests broad psychotropic potential.
Conclusions:
- Quetiapine is a versatile agent with established roles in pediatric mental health.
- Further examination of evidence supports its clinical application.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
96
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
96
01:24Mania and Antimanic Drugs: Overview
103
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
103
01:21Antipsychotic Drugs: Typical and Atypical Agents
123
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
123
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
129
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
129
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
261
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
261
01:20Antiepileptic Drugs: Potassium Channel Activators
127
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
127